Secukinumab is under clinical development by Novartis and currently in Phase II for Congenital Ichthyosis. According to GlobalData, Phase II drugs for Congenital Ichthyosis does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Secukinumab LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Secukinumab (Cosentyx, Zafrez, Fraizeron, Scapho Lyvi) is an immunosuppressive agent. It is formulated as freeze-dried preparation for powder for solution and solution in prefilled syringe or pre-filled pen for subcutaneous and intravenous route of administration. Cosentyx is indicated for the treatment of moderate to severe plaque psoriasis in patients 6 years and older who are candidates for systemic therapy or phototherapy; adult patients with active psoriatic arthritis. It is also indicated for the treatment of adult patients with active non-radiographic axial spondyloarthritis (nraxSpA) with objective signs of inflammation and also indicated for the treatment of psoriasis vulgaris, psoriatic arthritis, and pustular psoriasis in children. Cosentyx (secukinumab), used alone or in combination with methotrexate, in the juvenile idiopathic arthritis (JIA) categories of enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA) in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy. It is also indicated for the treatment for tendon injury.
Secukinumab is under development for the treatment of pyoderma gangrenosum, psoriasis, non-radiographic axial spondyloarthritis, hidradenitis suppurativa, giant cell arteritis, atopic dermatitis and ichthyosis, lichen planus, non-alcoholic fatty liver disease. The drug candidate was under development for the treatment of atopic dermatitis, alopecia areata, contact dermatitis, moderate-to-severe plaque psoriasis in pediatrics, rheumatoid arthritis, bronchial asthma, non-infectious uveitis in patients with Behcet’s disease, neutrophilia, dry eye syndrome, type 1 diabetes, severe Crohn's disease and relapsing-remitting multiple sclerosis (RRMS), relapsing multiple sclerosis, polymyalgia rheumatica and severe acute respiratory syndrome (SARS) associated with Covid-19 and Covid-19 associated pneumonia.
It was also under development for the treatment of Necrobiosis Lipoidica Diabeticorum, lupus nephritis, chronic cutaneous lupus erythematosus, active peripheral spondyloarthritis (pSpA), thyroid eye disease (Graves ophthalmopathy) and ankylosing spondylitis.
Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, hematologic diseases, solid tumors, immune disorders, and infections, among others. The company offers generic medicines and biosimilars through Sandoz. Novartis conducts research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR). The company operates through a network of subsidiaries and offices across the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Novartis is headquartered in Basel, Switzerland.
For a complete picture of Secukinumab’s drug-specific PTSR and LoA scores, buy the report here.